Selection of active clinical studies for BPDCN*
| Clinical study . | Mechanism of action . | Phase of study . | NCT # . | Clinical status . |
|---|---|---|---|---|
| BPDCN International Registry | N/A | N/A | NCT05430971 | Recruiting |
| Study of venetoclax, a BCL2 antagonist, for patients with BPDCN | BCL2 inhibition | 1 | NCT03485547 | Active, not recruiting |
| Combination chemotherapy in patients with newly diagnosed BPDCN | Multi-agent cytotoxic chemotherapy: idarubicin, methotrexate L-asparaginase Dexamethasone | 2 | NCT03599960 | Active, not recruiting |
| Study of IMGN632 in patients with untreated BPDCN and relapsed/refractory BPDCN | CD123 targeted | 2 | NCT03386513 | Active, not recruiting |
| Venetclax, SL401, and chemotherapy for treatment of BPDCN | BCL2 CD123 Cytotoxic chemotherapy | 2 | NCT04216524 | Recruiting |
| Tagraxofusp in patients with CD123+ or with BPDCN-IPh-like AML | CD123 targeted | 2 | NCT04342962 | Recruiting |
| Safety and efficacy of CD123-targeted CAR-NK for relapsed/refractory AML or BPDCN | CD123 targeted | 1/2 | NCT06006403 | Recruiting |
| First-in-human study of SAR443579 infusion R/R AML, B-cell ALL, high-risk MDS, or BPDCN | CD123 targeted | 1/2 | NCT05086315 | Recruiting |
| Genetically modified T-cell immunotherapy in treating patients with R/R AML and persistent/recurrent BPDCN | CD123 targeted | 1 | NCT02159495 | Recruiting |
| Venetoclax and decitabine in R/R AML or high-risk MDS | BCL2– and hypomethylating | 2 | NCT03404193 | Active, not recruiting |
| Flotetuzumab for R/R CD123+ hematologic malignancies | CD123 x CD3 targeted | 1 | NCT04681105 | Active, not recruiting |
| A study of MGD024 R/R hematologic malignancies | CD123 x CD3-bispecific | 1 | NCT05362773 | Recruiting |
| Cord blood transplant, cyclophosphamide, fludarabine, TBI in high-risk hematologic diseases | Immune-modulating + cytotoxic chemotherapy | 2 | NCT06013423 | Recruiting |
| Clinical study . | Mechanism of action . | Phase of study . | NCT # . | Clinical status . |
|---|---|---|---|---|
| BPDCN International Registry | N/A | N/A | NCT05430971 | Recruiting |
| Study of venetoclax, a BCL2 antagonist, for patients with BPDCN | BCL2 inhibition | 1 | NCT03485547 | Active, not recruiting |
| Combination chemotherapy in patients with newly diagnosed BPDCN | Multi-agent cytotoxic chemotherapy: idarubicin, methotrexate L-asparaginase Dexamethasone | 2 | NCT03599960 | Active, not recruiting |
| Study of IMGN632 in patients with untreated BPDCN and relapsed/refractory BPDCN | CD123 targeted | 2 | NCT03386513 | Active, not recruiting |
| Venetclax, SL401, and chemotherapy for treatment of BPDCN | BCL2 CD123 Cytotoxic chemotherapy | 2 | NCT04216524 | Recruiting |
| Tagraxofusp in patients with CD123+ or with BPDCN-IPh-like AML | CD123 targeted | 2 | NCT04342962 | Recruiting |
| Safety and efficacy of CD123-targeted CAR-NK for relapsed/refractory AML or BPDCN | CD123 targeted | 1/2 | NCT06006403 | Recruiting |
| First-in-human study of SAR443579 infusion R/R AML, B-cell ALL, high-risk MDS, or BPDCN | CD123 targeted | 1/2 | NCT05086315 | Recruiting |
| Genetically modified T-cell immunotherapy in treating patients with R/R AML and persistent/recurrent BPDCN | CD123 targeted | 1 | NCT02159495 | Recruiting |
| Venetoclax and decitabine in R/R AML or high-risk MDS | BCL2– and hypomethylating | 2 | NCT03404193 | Active, not recruiting |
| Flotetuzumab for R/R CD123+ hematologic malignancies | CD123 x CD3 targeted | 1 | NCT04681105 | Active, not recruiting |
| A study of MGD024 R/R hematologic malignancies | CD123 x CD3-bispecific | 1 | NCT05362773 | Recruiting |
| Cord blood transplant, cyclophosphamide, fludarabine, TBI in high-risk hematologic diseases | Immune-modulating + cytotoxic chemotherapy | 2 | NCT06013423 | Recruiting |
This table was created according to listings on clinicaltrials.gov, accessed July 2024 with search terms “blastic plasmacytoid dendritic cell neoplasm” and “BPDCN” in “conditions/disease” and “other terms” filter options. This table represents a selection of those studies listed on the website as either “active,” “recruiting,” or “active, not recruiting” and is not meant to be an exhaustive list of all clinical trials available all over the world, but rather a selection to provide an idea of ongoing or recently completed clinical trials in this rare disease field.